Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin

Transplantation

Volumn 84, Issue 5, 2007, Pages 598-604

  Grosskreutz, Celia ^a,b   Scigliano, Eileen ^a   Osman, Keren ^a   Isola, Luis ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Antithymocyte globulin; Graft versus host disease; Graft versus tumor effect; NST; RIC

Indexed keywords

CIPROFLOXACIN; CYCLOSPORIN; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; FLUDARABINE PHOSPHATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; VALACICLOVIR;

ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CHIMERA; COMORBIDITY; FEMALE; FOLLOW UP; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; AGED; ANTILYMPHOCYTE SERUM; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 34548800383     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000279294.84222.61     Document Type: Article

References (24)

1. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation 10.1182/blood-2002-08-2628. Blood 2003; 102: 756.
2. Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595.
3. Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning 10.1182/blood-2004-04-1506. Blood 2004; 104: 2254.
4. Ash RC, Horowitz MM, Gale RP, et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant 1991; 7: 443.
5. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468.
6. Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation. Biol Blood Marrow Transplant 2003; 9: 453.
7. Rowley SD, Goldberg SL, Pecora AL, et al. Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin. Biol Blood Marrow Transplant 2004; 10: 784.
8. Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441.
9. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387.
10. Sullivan K. Graft versus host disease. In: Blume KG FS, Appelbaum FR, ed. Thomas' Hematopoietic Cell Transplantation, 3rd Ed. Oxford, United Kingdom: Blakwell Publishing Ltd.; 2004:635.
11. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and post-grafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620.
12. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning 10.1200/JCO. 2005.08.136. J Clin Oncol 2005; 23: 1993.
13. Baron F SR. Current roles for allogeneic hematopoietic cell transplantation following nonmyeloablative or reduced-intensity conditioning. Clin Adv Hematol Oncol 2005; 3: 799.
14. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumabcontaining reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865.
15. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444.
16. Sayer HG, Kroger M, Beyer J, et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003; 31: 1089.
17. Hallemeier C, Girgis M, Blum W, et al. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. Biol Blood Marrow Transplant 2004; 10: 310.
18. Niederwieser D, Gentilini C, Hegenbart U, et al. Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias. Crit Rev Oncol/Hematol. 2005; 56: 275.
19. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS 10.1182/blood-2004-02-0414. Blood 2004; 104: 857.
20. de Lima M, Couriel D, Ghosh S, et al. Outcomes of older patients with myeloid leukemias treated with myeloablative intravenous busulfan-based conditioning regimens and allogeneic blood or marrow transplantation. ASH Annual Meeting Abstracts 2005; 106: 660.
21. Kroger N, Zabelina T, Kruger W, et al. Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Hematol 2001; 80: 209.
22. Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000; 26: 69.
23. Basara N, Roemer E, Kraut L, et al. Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: A single center experience. Bone Marrow Transplant 2002; 30: 651.
24. Thomson BG, Robertson KA, Gowan D, et al. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood 2000; 96: 2703.